These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21572644)

  • 21. Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma.
    Wang HY; Yao ZH; Tang H; Zhao Y; Zhang XS; Yao SN; Yang SJ; Liu YY
    Onco Targets Ther; 2016; 9():5663-5669. PubMed ID: 27713635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypersensitivity reaction studies of a polyethoxylated castor oil-free, liposome-based alternative paclitaxel formulation.
    Wang H; Cheng G; Du Y; Ye L; Chen W; Zhang L; Wang T; Tian J; Fu F
    Mol Med Rep; 2013 Mar; 7(3):947-52. PubMed ID: 23291923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessing the effectiveness of gabapentin in paclitaxel-induced arthralgia, myalgia, and neuropathic pain: An observational, cohort study.
    Patel P; Rajput HS; Chavda K; Mistry S; Bhagat S; Hadia R; Saiyed M; Khadela A
    J Oncol Pharm Pract; 2024 Jan; ():10781552231225148. PubMed ID: 38179645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A retrospective analysis of adverse events based on a dose and a schedule in patients who underwent paclitaxel- containing chemotherapy].
    Yoshimura T; Hirade K; Iihara H; Ishihara M; Komori Y; Okayasu S; Matsuura K; Yasuda T; Itoh Y
    Gan To Kagaku Ryoho; 2008 Oct; 35(10):1721-6. PubMed ID: 18931576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A study of adverse drug reactions in pediatric patients.
    Priyadharsini R; Surendiran A; Adithan C; Sreenivasan S; Sahoo FK
    J Pharmacol Pharmacother; 2011 Oct; 2(4):277-80. PubMed ID: 22025857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.
    Gradishar WJ; Tjulandin S; Davidson N; Shaw H; Desai N; Bhar P; Hawkins M; O'Shaughnessy J
    J Clin Oncol; 2005 Nov; 23(31):7794-803. PubMed ID: 16172456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced, recurrent, or metastatic cervical carcinoma.
    Li Y; Zeng J; Huang M; An J; Bai P; Wu L; Zhang R
    Cancer; 2017 Feb; 123(3):420-425. PubMed ID: 27696395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval.
    Yamamoto Y; Kawano I; Iwase H
    Onco Targets Ther; 2011; 4():123-36. PubMed ID: 21792318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
    Cohen MH; Gootenberg J; Keegan P; Pazdur R
    Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer.
    Shepherd FA; Latreille J; Paul K; Eisenhauer E
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):84-90. PubMed ID: 9007130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer.
    Moulder SL; Holmes FA; Tolcher AW; Thall P; Broglio K; Valero V; Buzdar AU; Arbuck SG; Seidman A; Hortobagyi GN
    Cancer; 2010 Feb; 116(4):814-21. PubMed ID: 20052721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-agent paclitaxel in patients with previously untreated stage IV epithelial ovarian cancer. London Gynaecological Oncology and North Thames Gynaecological Oncology Groups.
    Gore ME; Rustin G; Slevin M; Gallagher C; Penson R; Osborne R; Ledermann J; Cameron T; Thompson JM
    Br J Cancer; 1997; 75(5):710-4. PubMed ID: 9043029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spontaneous adverse drug reaction monitoring in oncology: Our experience.
    Kaur K; Sood M; Bhagat S; Singh T; Jain M; Arora D; Sekhon JS; Kaushal S
    Indian J Cancer; 2015; 52(3):467-70. PubMed ID: 26905171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overview of Taxol safety.
    Onetto N; Canetta R; Winograd B; Catane R; Dougan M; Grechko J; Burroughs J; Rozencweig M
    J Natl Cancer Inst Monogr; 1993; (15):131-9. PubMed ID: 7912519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.
    Milojkovic Kerklaan B; Diéras V; Le Tourneau C; Mergui-Roelvink M; Huitema AD; Rosing H; Beijnen JH; Marreaud S; Govaerts AS; Piccart-Gebhart MJ; Schellens JH; Awada A
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):53-62. PubMed ID: 23053259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
    Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.
    Cantù MG; Buda A; Parma G; Rossi R; Floriani I; Bonazzi C; Dell'Anna T; Torri V; Colombo N
    J Clin Oncol; 2002 Mar; 20(5):1232-7. PubMed ID: 11870165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical toxicities encountered with paclitaxel (Taxol).
    Rowinsky EK; Eisenhauer EA; Chaudhry V; Arbuck SG; Donehower RC
    Semin Oncol; 1993 Aug; 20(4 Suppl 3):1-15. PubMed ID: 8102012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.